Addressing the Treatment Gap in Advanced Liposarcoma
Novel therapeutic compounds to treat advanced liposarcoma.
Patients diagnosed with advanced liposarcoma (LPS) face a significant treatment challenge, as current chemotherapy approaches exhibit low response rates of only 25%, leading to a dismal overall survival at 5 years, ranging between 20% to 34%.
Despite extensive efforts, there has been no substantial improvement in prognosis for nearly two decades. The aggressive clinical behavior of LPS and its resistance to chemotherapy have been linked to the aberrant activation of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway. However, existing attempts to target AKT clinically have not yielded successful outcomes. A critical need exists for a novel therapeutic technology that can effectively combat LPS by targeting AKT in a precise and efficient manner.
The Technology: Revolutionary IWS1 Inhibitors
Researchers at The Ohio State University have discovered how the phosphorylation of the transcription elongation factor IWS1 by AKT contributes to LPS tumor biology and have developed novel compounds designed to inhibit IWS1. By targeting IWS1, we aim to disrupt the AKT-mediated phosphorylation process that promotes the maintenance of cancer stem cells and contributes to a "metastable" cell phenotype characterized by mesenchymal/epithelial plasticity. This cutting-edge approach offers a promising solution to combat LPS progression and metastasis effectively.